Forbion related stories
All articles and analysis
Side Letter: PE's entry barrier; Pictet's double close; Niche index updateMonday is a bank holiday in the UK due to King Charles's coronation this weekend, so Side Letter will return on Tuesday. For now, institutional investors face a knowledge gap when pondering an entry into private markets. Plus: nice news for niche investors. Here’s today's brief, for our valued subscribers only.
Side Letter: Thoma Bravo's timing; PE's job creation credentials; Korea's VC supportThoma Bravo's apparent eagerness to hit the fundraising trail could prove advantageous at a time when the process is slower-going. Plus: Invest Europe shines a light on PE's job creation credentials; and Korea's government wants to back domestic VCs. Here’s today's brief, for our valued subscribers only.
Meeker's Bond gives ESG a big boost by signing PRIBond is believed to be the first major US venture firm to sign the UN’s Principles of Responsible Investment.
Port in a storm: VCs are finding safe haven in Europe's flourishing marketAs economic troubles continue to roil the world’s biggest economies, VCs are thriving in a European market where $1bn-plus unicorns are making quite a splash.
Port in a storm: VCs are finding safe haven in Europe's flourishing marketAs economic troubles continue to roil the world’s biggest economies, VCs are thriving in a European market where $1bn-plus unicorns are making quite a splash.
CHART: The biggest dedicated life sciences capital raisersDedicated life sciences firms with strong AUM growth have been prime targets for larger GPs recently – here's a list of firms ranked by capital raised.
Precirix scores Series BPrecirix, a developer of precision radiopharmaceuticals in oncology, has raised 80 million euros in Series B financing.
Complement Therapeutics rings in 5m eurosComplement Therapeutics Ltd, a preclinical stage University of Manchester spinout, has secured 5 million euros in seed funding.
- Rectify Pharmaceuticals lands $100m Series A
Rectify Pharmaceuticals Inc, a biotechnology company, has secured $100 million in Series A financing.
- VC-backed Gyroscope postpones IPO plans
London-based Gyroscope Therapeutics, a gene therapy company focused on treating eye diseases, has postponed its IPO plans, citing market conditions as the reason.